25 XP   0   0   10

XSpray Pharma AB
Buy, Hold or Sell?

Let's analyse XSpray Pharma AB together

PenkeI guess you are interested in XSpray Pharma AB. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of XSpray Pharma AB. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about XSpray Pharma AB

I send you an email if I find something interesting about XSpray Pharma AB.

Quick analysis of XSpray Pharma AB (30 sec.)










What can you expect buying and holding a share of XSpray Pharma AB? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr22.19
Expected worth in 1 year
kr26.58
How sure are you?
37.9%

+ What do you gain per year?

Total Gains per Share
kr4.40
Return On Investment
10.8%

For what price can you sell your share?

Current Price per Share
kr40.65
Expected price per share
kr38.60 - kr47.90
How sure are you?
50%

1. Valuation of XSpray Pharma AB (5 min.)




Live pricePrice per Share (EOD)

kr40.65

Intrinsic Value Per Share

kr-67.71 - kr-78.49

Total Value Per Share

kr-45.52 - kr-56.30

2. Growth of XSpray Pharma AB (5 min.)




Is XSpray Pharma AB growing?

Current yearPrevious yearGrowGrow %
How rich?$63.7m$31m$22.7m42.3%

How much money is XSpray Pharma AB making?

Current yearPrevious yearGrowGrow %
Making money-$4.1m-$2.9m-$1.1m-27.3%
Net Profit Margin-33.3%0.0%--

How much money comes from the company's main activities?

3. Financial Health of XSpray Pharma AB (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#444 / 1009

Most Revenue
#527 / 1009

Most Profit
#396 / 1009

Most Efficient
#509 / 1009

What can you expect buying and holding a share of XSpray Pharma AB? (5 min.)

Welcome investor! XSpray Pharma AB's management wants to use your money to grow the business. In return you get a share of XSpray Pharma AB.

What can you expect buying and holding a share of XSpray Pharma AB?

First you should know what it really means to hold a share of XSpray Pharma AB. And how you can make/lose money.

Speculation

The Price per Share of XSpray Pharma AB is kr40.65. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of XSpray Pharma AB.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in XSpray Pharma AB, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr22.19. Based on the TTM, the Book Value Change Per Share is kr1.10 per quarter. Based on the YOY, the Book Value Change Per Share is kr2.61 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of XSpray Pharma AB.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.16-0.4%-0.13-0.3%-0.10-0.2%-0.07-0.2%-0.05-0.1%
Usd Book Value Change Per Share0.100.2%0.100.2%0.240.6%0.060.1%0.070.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.100.2%0.100.2%0.240.6%0.060.1%0.070.2%
Usd Price Per Share3.68-4.36-5.21-7.49-6.33-
Price to Earnings Ratio-5.74--8.87--15.67--40.77--54.68-
Price-to-Total Gains Ratio37.89--10.57--13.84-815.33-581.16-
Price to Book Ratio1.80-2.64-1.10-5.61-5.72-
Price-to-Total Gains Ratio37.89--10.57--13.84-815.33-581.16-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.735735
Number of shares267
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.100.06
Usd Total Gains Per Share0.100.06
Gains per Quarter (267 shares)26.9715.38
Gains per Year (267 shares)107.8761.50
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101089806252
202162060123114
303243140185176
404314220246238
505395300308300
606476380369362
707557460431424
808638540492486
909719620554548
100107910700615610

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.027.00.06.9%2.027.00.06.9%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%7.013.00.035.0%11.017.01.037.9%11.017.01.037.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.029.00.0%0.00.029.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%7.013.00.035.0%11.017.01.037.9%11.017.01.037.9%

Fundamentals of XSpray Pharma AB

About XSpray Pharma AB

Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include XS003 for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and XS004 for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is headquartered in Solna, Sweden.

Fundamental data was last updated by Penke on 2024-04-04 12:42:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of XSpray Pharma AB.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit XSpray Pharma AB earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare XSpray Pharma AB to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of XSpray Pharma AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-33.3%+33.3%
TTM-33.3%YOY--33.3%
TTM-33.3%5Y-6.7%-26.7%
5Y-6.7%10Y-1,236.7%+1,230.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--200.1%+200.1%
TTM-33.3%-216.8%+183.5%
YOY--288.3%+288.3%
5Y-6.7%-449.1%+442.4%
10Y-1,236.7%-605.5%-631.2%
1.1.2. Return on Assets

Shows how efficient XSpray Pharma AB is using its assets to generate profit.

  • Above 5% is considered healthy but always compare XSpray Pharma AB to the Biotechnology industry mean.
  • -7.1% Return on Assets means that XSpray Pharma AB generated kr-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of XSpray Pharma AB:

  • The MRQ is -7.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.1%TTM-7.0%-0.1%
TTM-7.0%YOY-5.7%-1.3%
TTM-7.0%5Y-4.7%-2.3%
5Y-4.7%10Y-3.4%-1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.1%-13.3%+6.2%
TTM-7.0%-12.8%+5.8%
YOY-5.7%-11.7%+6.0%
5Y-4.7%-13.9%+9.2%
10Y-3.4%-15.7%+12.3%
1.1.3. Return on Equity

Shows how efficient XSpray Pharma AB is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare XSpray Pharma AB to the Biotechnology industry mean.
  • -7.9% Return on Equity means XSpray Pharma AB generated kr-0.08 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of XSpray Pharma AB:

  • The MRQ is -7.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.9%TTM-7.8%0.0%
TTM-7.8%YOY-4.6%-3.2%
TTM-7.8%5Y-4.7%-3.1%
5Y-4.7%10Y-3.4%-1.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.9%-16.9%+9.0%
TTM-7.8%-16.1%+8.3%
YOY-4.6%-15.1%+10.5%
5Y-4.7%-19.3%+14.6%
10Y-3.4%-20.2%+16.8%

1.2. Operating Efficiency of XSpray Pharma AB.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient XSpray Pharma AB is operating .

  • Measures how much profit XSpray Pharma AB makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare XSpray Pharma AB to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of XSpray Pharma AB:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-33.2%+33.2%
TTM-33.2%YOY--33.2%
TTM-33.2%5Y-6.6%-26.6%
5Y-6.6%10Y-1,234.5%+1,227.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM-33.2%-232.5%+199.3%
YOY--298.2%+298.2%
5Y-6.6%-492.1%+485.5%
10Y-1,234.5%-632.4%-602.1%
1.2.2. Operating Ratio

Measures how efficient XSpray Pharma AB is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of XSpray Pharma AB:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.355-0.355
TTM0.355YOY-+0.355
TTM0.3555Y0.071+0.284
5Y0.07110Y11.696-11.625
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.231-3.231
TTM0.3553.310-2.955
YOY-3.890-3.890
5Y0.0715.739-5.668
10Y11.6967.876+3.820

1.3. Liquidity of XSpray Pharma AB.

1.3. Liquidity
1.3.1. Current Ratio

Measures if XSpray Pharma AB is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.46 means the company has kr5.46 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of XSpray Pharma AB:

  • The MRQ is 5.459. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.609. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.459TTM3.609+1.850
TTM3.609YOY6.714-3.105
TTM3.6095Y9.485-5.876
5Y9.48510Y12.405-2.920
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.4593.890+1.569
TTM3.6094.173-0.564
YOY6.7145.344+1.370
5Y9.4856.126+3.359
10Y12.4056.448+5.957
1.3.2. Quick Ratio

Measures if XSpray Pharma AB is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare XSpray Pharma AB to the Biotechnology industry mean.
  • A Quick Ratio of 4.27 means the company can pay off kr4.27 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of XSpray Pharma AB:

  • The MRQ is 4.272. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.698. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.272TTM2.698+1.574
TTM2.698YOY6.344-3.646
TTM2.6985Y9.096-6.397
5Y9.09610Y12.028-2.933
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2723.514+0.758
TTM2.6983.998-1.300
YOY6.3445.380+0.964
5Y9.0966.105+2.991
10Y12.0286.404+5.624

1.4. Solvency of XSpray Pharma AB.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of XSpray Pharma AB assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare XSpray Pharma AB to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.09 means that XSpray Pharma AB assets are financed with 9.4% credit (debt) and the remaining percentage (100% - 9.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of XSpray Pharma AB:

  • The MRQ is 0.094. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.091. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.094TTM0.091+0.002
TTM0.091YOY0.429-0.337
TTM0.0915Y0.134-0.043
5Y0.13410Y0.109+0.025
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0940.339-0.245
TTM0.0910.336-0.245
YOY0.4290.271+0.158
5Y0.1340.366-0.232
10Y0.1090.389-0.280
1.4.2. Debt to Equity Ratio

Measures if XSpray Pharma AB is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare XSpray Pharma AB to the Biotechnology industry mean.
  • A Debt to Equity ratio of 10.4% means that company has kr0.10 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of XSpray Pharma AB:

  • The MRQ is 0.104. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.103. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.104TTM0.103+0.000
TTM0.103YOY0.032+0.072
TTM0.1035Y0.059+0.045
5Y0.05910Y0.059+0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1040.388-0.284
TTM0.1030.402-0.299
YOY0.0320.335-0.303
5Y0.0590.426-0.367
10Y0.0590.461-0.402

2. Market Valuation of XSpray Pharma AB

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings XSpray Pharma AB generates.

  • Above 15 is considered overpriced but always compare XSpray Pharma AB to the Biotechnology industry mean.
  • A PE ratio of -5.74 means the investor is paying kr-5.74 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of XSpray Pharma AB:

  • The EOD is -5.828. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.735. Based on the earnings, the company is expensive. -2
  • The TTM is -8.865. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.828MRQ-5.735-0.093
MRQ-5.735TTM-8.865+3.130
TTM-8.865YOY-15.675+6.810
TTM-8.8655Y-40.774+31.909
5Y-40.77410Y-54.679+13.906
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.828-2.264-3.564
MRQ-5.735-2.629-3.106
TTM-8.865-2.680-6.185
YOY-15.675-4.145-11.530
5Y-40.774-6.257-34.517
10Y-54.679-6.254-48.425
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of XSpray Pharma AB:

  • The EOD is -6.409. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.307. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.984. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.409MRQ-6.307-0.102
MRQ-6.307TTM-5.984-0.322
TTM-5.984YOY-7.543+1.559
TTM-5.9845Y-16.654+10.670
5Y-16.65410Y-19.228+2.574
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.409-2.973-3.436
MRQ-6.307-3.333-2.974
TTM-5.984-3.553-2.431
YOY-7.543-5.605-1.938
5Y-16.654-8.376-8.278
10Y-19.228-8.865-10.363
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of XSpray Pharma AB is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.80 means the investor is paying kr1.80 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of XSpray Pharma AB:

  • The EOD is 1.832. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.803. Based on the equity, the company is underpriced. +1
  • The TTM is 2.637. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.832MRQ1.803+0.029
MRQ1.803TTM2.637-0.835
TTM2.637YOY1.099+1.538
TTM2.6375Y5.606-2.969
5Y5.60610Y5.720-0.114
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.8321.896-0.064
MRQ1.8032.115-0.312
TTM2.6372.093+0.544
YOY1.0992.884-1.785
5Y5.6063.542+2.064
10Y5.7203.916+1.804
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of XSpray Pharma AB compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.0561.099-4%2.610-60%0.627+68%0.765+38%
Book Value Per Share--22.18718.759+18%10.827+105%13.545+64%10.936+103%
Current Ratio--5.4593.609+51%6.714-19%9.485-42%12.405-56%
Debt To Asset Ratio--0.0940.091+3%0.429-78%0.134-30%0.109-14%
Debt To Equity Ratio--0.1040.103+0%0.032+226%0.059+76%0.059+76%
Dividend Per Share----0%-0%-0%-0%
Eps---1.744-1.437-18%-1.053-40%-0.759-56%-0.553-68%
Free Cash Flow Per Share---1.586-2.059+30%-1.908+20%-1.503-5%-1.158-27%
Free Cash Flow To Equity Per Share--1.2140.466+161%-1.157+195%-0.159+113%0.124+879%
Gross Profit Margin--1.1271.032+9%1.000+13%1.089+4%1.061+6%
Intrinsic Value_10Y_max---78.490--------
Intrinsic Value_10Y_min---67.710--------
Intrinsic Value_1Y_max---7.166--------
Intrinsic Value_1Y_min---7.038--------
Intrinsic Value_3Y_max---22.064--------
Intrinsic Value_3Y_min---21.053--------
Intrinsic Value_5Y_max---37.604--------
Intrinsic Value_5Y_min---34.857--------
Market Cap1270454775.000+2%1250140000.0001483759912.500-16%1771292112.500-29%2703473871.875-54%2261976928.017-45%
Net Profit Margin----0.3330%-0%-0.0670%-12.3670%
Operating Margin----0.3320%-0%-0.0660%-12.3450%
Operating Ratio---0.355-100%-0%0.071-100%11.696-100%
Pb Ratio1.832+2%1.8032.637-32%1.099+64%5.606-68%5.720-68%
Pe Ratio-5.828-2%-5.735-8.865+55%-15.675+173%-40.774+611%-54.679+853%
Price Per Share40.650+2%40.00047.475-16%56.675-29%81.450-51%68.891-42%
Price To Free Cash Flow Ratio-6.409-2%-6.307-5.984-5%-7.543+20%-16.654+164%-19.228+205%
Price To Total Gains Ratio38.507+2%37.891-10.569+128%-13.842+137%815.332-95%581.158-93%
Quick Ratio--4.2722.698+58%6.344-33%9.096-53%12.028-64%
Return On Assets---0.071-0.070-1%-0.057-20%-0.047-34%-0.034-52%
Return On Equity---0.079-0.078-1%-0.046-42%-0.047-40%-0.034-56%
Total Gains Per Share--1.0561.099-4%2.610-60%0.627+68%0.765+38%
Usd Book Value--63724654.70053878281.925+18%31097053.075+105%40566254.465+57%32558422.984+96%
Usd Book Value Change Per Share--0.0970.101-4%0.240-60%0.058+68%0.070+38%
Usd Book Value Per Share--2.0391.724+18%0.995+105%1.245+64%1.005+103%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.160-0.132-18%-0.097-40%-0.070-56%-0.051-68%
Usd Free Cash Flow---4554288.208-5913259.527+30%-5478733.375+20%-4411664.090-3%-3392205.755-26%
Usd Free Cash Flow Per Share---0.146-0.189+30%-0.175+20%-0.138-5%-0.106-27%
Usd Free Cash Flow To Equity Per Share--0.1120.043+161%-0.106+195%-0.015+113%0.011+879%
Usd Market Cap116754793.823+2%114887866.000136357535.959-16%162781745.139-29%248449248.825-54%207875679.685-45%
Usd Price Per Share3.736+2%3.6764.363-16%5.208-29%7.485-51%6.331-42%
Usd Profit---5008182.400-4114937.375-18%-2992884.325-40%-2317033.345-54%-1681996.223-66%
Usd Revenue---670938.925-100%-0%134187.785-100%94794.996-100%
Usd Total Gains Per Share--0.0970.101-4%0.240-60%0.058+68%0.070+38%
 EOD+6 -2MRQTTM+16 -16YOY+12 -185Y+14 -1810Y+14 -18

3.2. Fundamental Score

Let's check the fundamental score of XSpray Pharma AB based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-5.828
Price to Book Ratio (EOD)Between0-11.832
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.272
Current Ratio (MRQ)Greater than15.459
Debt to Asset Ratio (MRQ)Less than10.094
Debt to Equity Ratio (MRQ)Less than10.104
Return on Equity (MRQ)Greater than0.15-0.079
Return on Assets (MRQ)Greater than0.05-0.071
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of XSpray Pharma AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.214
Ma 20Greater thanMa 5041.100
Ma 50Greater thanMa 10041.638
Ma 100Greater thanMa 20039.420
OpenGreater thanClose40.550
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets765,263
Total Liabilities71,850
Total Stockholder Equity693,413
 As reported
Total Liabilities 71,850
Total Stockholder Equity+ 693,413
Total Assets = 765,263

Assets

Total Assets765,263
Total Current Assets217,815
Long-term Assets547,448
Total Current Assets
Cash And Cash Equivalents 166,303
Net Receivables 4,165
Inventory 43,781
Other Current Assets 3,566
Total Current Assets  (as reported)217,815
Total Current Assets  (calculated)217,815
+/-0
Long-term Assets
Property Plant Equipment 107,651
Intangible Assets 436,780
Long-term Assets Other 1
Long-term Assets  (as reported)547,448
Long-term Assets  (calculated)544,432
+/- 3,016

Liabilities & Shareholders' Equity

Total Current Liabilities39,903
Long-term Liabilities31,947
Total Stockholder Equity693,413
Total Current Liabilities
Short-term Debt 4,861
Accounts payable 12,472
Other Current Liabilities 22,570
Total Current Liabilities  (as reported)39,903
Total Current Liabilities  (calculated)39,903
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt31,947
Long-term Liabilities  (as reported)31,947
Long-term Liabilities  (calculated)31,947
+/- 0
Total Stockholder Equity
Common Stock31,254
Retained Earnings -554,725
Accumulated Other Comprehensive Income 792
Other Stockholders Equity 1,216,092
Total Stockholder Equity (as reported)693,413
Total Stockholder Equity (calculated)693,413
+/-0
Other
Capital Stock31,254
Cash and Short Term Investments 166,303
Common Stock Shares Outstanding 29,523
Liabilities and Stockholders Equity 765,263
Net Debt -129,495
Net Invested Capital 693,413
Net Working Capital 177,912
Property Plant and Equipment Gross 147,041
Short Long Term Debt Total 36,808



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-30
> Total Assets 
0
51,862
0
43,673
175,622
161,413
241,496
235,929
231,022
312,485
307,376
302,492
292,238
400,672
383,061
365,639
367,708
605,303
594,178
578,740
566,749
622,903
592,430
566,345
539,969
585,430
547,840
561,120
703,305
765,263
765,263703,305561,120547,840585,430539,969566,345592,430622,903566,749578,740594,178605,303367,708365,639383,061400,672292,238302,492307,376312,485231,022235,929241,496161,413175,62243,673051,8620
   > Total Current Assets 
0
31,260
0
13,321
139,069
117,342
190,971
173,899
160,055
226,861
199,163
167,297
136,233
216,126
176,438
141,604
119,714
331,015
296,406
256,277
226,375
282,065
205,871
152,729
99,098
132,229
81,988
81,116
210,818
217,815
217,815210,81881,11681,988132,22999,098152,729205,871282,065226,375256,277296,406331,015119,714141,604176,438216,126136,233167,297199,163226,861160,055173,899190,971117,342139,06913,321031,2600
       Cash And Cash Equivalents 
0
28,803
0
12,024
137,679
115,512
188,889
171,815
157,922
221,266
192,850
162,338
130,657
209,872
172,740
137,716
116,622
325,598
292,265
253,737
216,543
271,881
196,212
142,581
89,834
120,166
59,395
31,543
132,480
166,303
166,303132,48031,54359,395120,16689,834142,581196,212271,881216,543253,737292,265325,598116,622137,716172,740209,872130,657162,338192,850221,266157,922171,815188,889115,512137,67912,024028,8030
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
5,017
2,436
1,980
1,889
3,316
1,706
1,504
3,996
2,503
2,138
270
1,614
3,513
4,001
2,636
35,336
4,165
4,16535,3362,6364,0013,5131,6142702,1382,5033,9961,5041,7063,3161,8891,9802,4365,0170000000000000
       Other Current Assets 
0
2,457
0
1,297
1,390
1,830
2,082
2,084
2,133
5,595
6,313
4,959
5,576
6,254
3,698
3,888
3,092
5,417
4,141
2,540
9,832
3,985
3,460
-1
2,675
-2
1
1,654
-1
3,566
3,566-11,6541-22,675-13,4603,9859,8322,5404,1415,4173,0923,8883,6986,2545,5764,9596,3135,5952,1332,0842,0821,8301,3901,29702,4570
   > Long-term Assets 
0
20,602
0
30,352
36,552
44,071
50,525
62,030
70,967
85,624
108,213
135,195
156,005
184,545
206,623
224,035
247,994
274,288
297,773
322,464
340,374
340,838
386,560
413,616
440,871
453,200
465,852
480,004
492,487
547,448
547,448492,487480,004465,852453,200440,871413,616386,560340,838340,374322,464297,773274,288247,994224,035206,623184,545156,005135,195108,21385,62470,96762,03050,52544,07136,55230,352020,6020
       Property Plant Equipment 
0
480
0
1,053
2,092
2,461
2,692
6,301
7,195
13,730
18,265
36,490
34,508
43,030
44,633
36,443
40,826
42,669
40,683
38,719
40,122
44,601
64,309
65,465
128,728
64,604
63,388
62,378
66,081
107,651
107,65166,08162,37863,38864,604128,72865,46564,30944,60140,12238,71940,68342,66940,82636,44344,63343,03034,50836,49018,26513,7307,1956,3012,6922,4612,0921,05304800
       Intangible Assets 
0
20,120
0
29,298
34,459
41,609
47,832
55,728
63,771
71,893
89,947
98,704
121,496
141,515
161,989
187,542
207,167
231,618
257,088
283,744
300,252
296,236
322,249
348,150
376,506
385,597
399,464
414,626
423,405
436,780
436,780423,405414,626399,464385,597376,506348,150322,249296,236300,252283,744257,088231,618207,167187,542161,989141,515121,49698,70489,94771,89363,77155,72847,83241,60934,45929,298020,1200
       Other Assets 
0
0
0
0
73,105
0
0
0
0
0
0
0
0
369,091
161,989
192,916
207,167
231,618
257,088
283,743
300,251
296,236
-1
348,150
376,506
1
-1
417,625
426,405
0
0426,405417,625-11376,506348,150-1296,236300,251283,743257,088231,618207,167192,916161,989369,0910000000073,1050000
> Total Liabilities 
0
5,388
0
2,851
14,471
5,754
4,070
5,831
5,041
10,769
14,163
20,331
20,660
26,957
19,568
17,492
19,281
22,716
21,137
20,956
22,900
31,151
19,612
21,828
859,806
29,411
26,649
91,061
42,885
71,850
71,85042,88591,06126,64929,411859,80621,82819,61231,15122,90020,95621,13722,71619,28117,49219,56826,95720,66020,33114,16310,7695,0415,8314,0705,75414,4712,85105,3880
   > Total Current Liabilities 
0
5,388
0
2,851
14,470
5,754
4,070
5,831
5,041
10,769
7,530
15,193
15,496
22,503
15,528
19,247
16,086
19,818
18,521
18,838
21,239
29,966
18,734
21,461
23,779
28,851
26,174
90,684
42,583
39,903
39,90342,58390,68426,17428,85123,77921,46118,73429,96621,23918,83818,52119,81816,08619,24715,52822,50315,49615,1937,53010,7695,0415,8314,0705,75414,4702,85105,3880
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
1,644
139
139
876
1,319
1,767
1,906
1,958
2,078
2,095
2,064
2,048
2,121
2,105
1,888
1,566
1,065
571
366
4,861
4,8613665711,0651,5661,8882,1052,1212,0482,0642,0952,0781,9581,9061,7671,3198761391391,6440000000000
       Accounts payable 
0
4,343
0
1,397
12,933
2,890
3,006
3,531
2,865
7,780
3,394
10,281
12,163
11,876
4,192
6,583
3,170
8,438
6,657
4,887
8,483
16,865
8,127
7,782
11,971
14,786
12,941
20,485
16,092
12,472
12,47216,09220,48512,94114,78611,9717,7828,12716,8658,4834,8876,6578,4383,1706,5834,19211,87612,16310,2813,3947,7802,8653,5313,0062,89012,9331,39704,3430
       Other Current Liabilities 
0
1,045
0
1,454
1,537
2,863
1,064
2,300
2,176
2,989
2,492
4,773
3,194
9,751
10,017
10,897
11,010
9,422
9,786
11,856
10,692
9,477
8,486
11,574
9,920
12,499
12,168
46,260
5,867
22,570
22,5705,86746,26012,16812,4999,92011,5748,4869,47710,69211,8569,7869,42211,01010,89710,0179,7513,1944,7732,4922,9892,1762,3001,0642,8631,5371,45401,0450
   > Long-term Liabilities 
0
0
0
0
1
0
0
0
0
0
6,633
5,138
5,164
4,454
4,040
-1,755
3,195
2,898
2,616
2,118
1,661
1,185
878
367
836,027
560
475
377
302
31,947
31,947302377475560836,0273678781,1851,6612,1182,6162,8983,195-1,7554,0404,4545,1645,1386,6330000010000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,195
2,898
2,616
2,118
1,661
1,185
878
367
323
560
475
377
302
0
03023774755603233678781,1851,6612,1182,6162,8983,1950000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
161,989
187,542
207,167
231,618
257,088
283,744
300,252
296,236
322,249
348,150
376,506
385,597
0
0
423,405
0
0423,40500385,597376,506348,150322,249296,236300,252283,744257,088231,618207,167187,542161,98900000000000000
> Total Stockholder Equity
0
46,474
0
40,822
161,151
155,660
237,426
230,098
225,981
301,716
293,213
282,161
271,578
373,715
363,493
348,147
348,427
582,587
573,041
557,784
543,849
591,752
572,818
544,517
-319,837
556,019
521,191
470,059
660,420
693,413
693,413660,420470,059521,191556,019-319,837544,517572,818591,752543,849557,784573,041582,587348,427348,147363,493373,715271,578282,161293,213301,716225,981230,098237,426155,660161,15140,822046,4740
   Common Stock
0
6,356
0
6,356
12,356
12,356
13,706
13,706
13,706
15,076
15,076
15,076
15,076
16,752
16,752
16,752
17,031
18,893
19,068
19,068
19,068
20,680
20,680
20,680
20,680
22,680
22,680
22,680
28,946
31,254
31,25428,94622,68022,68022,68020,68020,68020,68020,68019,06819,06819,06818,89317,03116,75216,75216,75215,07615,07615,07615,07613,70613,70613,70612,35612,3566,35606,3560
   Retained Earnings Total Equity000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
976
976
982
792
79298297697600000000000000000000000000
   Capital Surplus 000000000000000000000000000000
   Treasury Stock000000000000000000000000000000
   Other Stockholders Equity 
0
20,302
0
29,666
34,921
42,166
48,483
56,473
64,610
337,967
278,137
267,085
337,967
451,242
451,552
451,552
463,113
710,383
714,574
716,268
716,224
814,459
814,460
815,024
-340,517
908,396
907,420
907,690
1,130,721
1,216,092
1,216,0921,130,721907,690907,420908,396-340,517815,024814,460814,459716,224716,268714,574710,383463,113451,552451,552451,242337,967267,085278,137337,96764,61056,47348,48342,16634,92129,666020,3020



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-9,194
Gross Profit-9,194-9,194
 
Operating Income (+$)
Gross Profit-9,194
Operating Expense-200,632
Operating Income-209,826-209,826
 
Operating Expense (+$)
Research Development33,585
Selling General Administrative158,096
Selling And Marketing Expenses0
Operating Expense200,632191,681
 
Net Interest Income (+$)
Interest Income1,757
Interest Expense-675
Other Finance Cost-0
Net Interest Income1,082
 
Pretax Income (+$)
Operating Income-209,826
Net Interest Income1,082
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-179,684-239,968
EBIT - interestExpense = -210,501
-179,684
-178,992
Interest Expense675
Earnings Before Interest and Taxes (EBIT)-209,826-179,009
Earnings Before Interest and Taxes (EBITDA)-200,632
 
After tax Income (+$)
Income Before Tax-179,684
Tax Provision--17
Net Income From Continuing Ops-180,391-179,667
Net Income-179,667
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses209,826
Total Other Income/Expenses Net30,142-1,082
 

Technical Analysis of XSpray Pharma AB
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of XSpray Pharma AB. The general trend of XSpray Pharma AB is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine XSpray Pharma AB's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of XSpray Pharma AB.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 41.20 < 45.00 < 47.90.

The bearish price targets are: 39.20 > 39.00 > 38.60.

Tweet this
XSpray Pharma AB Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of XSpray Pharma AB. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

XSpray Pharma AB Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of XSpray Pharma AB. The current macd is -0.41500779.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the XSpray Pharma AB price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for XSpray Pharma AB. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the XSpray Pharma AB price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
XSpray Pharma AB Daily Moving Average Convergence/Divergence (MACD) ChartXSpray Pharma AB Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of XSpray Pharma AB. The current adx is 13.28.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy XSpray Pharma AB shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
XSpray Pharma AB Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of XSpray Pharma AB. The current sar is 43.15.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
XSpray Pharma AB Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of XSpray Pharma AB. The current rsi is 47.21. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
XSpray Pharma AB Daily Relative Strength Index (RSI) ChartXSpray Pharma AB Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of XSpray Pharma AB. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the XSpray Pharma AB price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
XSpray Pharma AB Daily Stochastic Oscillator ChartXSpray Pharma AB Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of XSpray Pharma AB. The current cci is -47.64584506.

XSpray Pharma AB Daily Commodity Channel Index (CCI) ChartXSpray Pharma AB Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of XSpray Pharma AB. The current cmo is -5.012434.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
XSpray Pharma AB Daily Chande Momentum Oscillator (CMO) ChartXSpray Pharma AB Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of XSpray Pharma AB. The current willr is -45.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that XSpray Pharma AB is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
XSpray Pharma AB Daily Williams %R ChartXSpray Pharma AB Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of XSpray Pharma AB.

XSpray Pharma AB Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of XSpray Pharma AB. The current atr is 1.55325858.

XSpray Pharma AB Daily Average True Range (ATR) ChartXSpray Pharma AB Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of XSpray Pharma AB. The current obv is 389,972.

XSpray Pharma AB Daily On-Balance Volume (OBV) ChartXSpray Pharma AB Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of XSpray Pharma AB. The current mfi is 48.78.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
XSpray Pharma AB Daily Money Flow Index (MFI) ChartXSpray Pharma AB Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for XSpray Pharma AB.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-24MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

XSpray Pharma AB Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of XSpray Pharma AB based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5047.214
Ma 20Greater thanMa 5041.100
Ma 50Greater thanMa 10041.638
Ma 100Greater thanMa 20039.420
OpenGreater thanClose40.550
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of XSpray Pharma AB with someone you think should read this too:
  • Are you bullish or bearish on XSpray Pharma AB? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about XSpray Pharma AB? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about XSpray Pharma AB

I send you an email if I find something interesting about XSpray Pharma AB.


Comments

How you think about this?

Leave a comment

Stay informed about XSpray Pharma AB.

Receive notifications about XSpray Pharma AB in your mailbox!